ResMed Inc., the market leader in continuous positive airway pressure (CPAP) for sleep apnea, has invested €9m ($11.7m) in Nyxoah SA as part of a €25m ($32.6m) funding round by the Belgian company.
Nyxoah’s Genio implantable neurostimulation system for treating obstructive sleep apnea (OSA) is CE marked in Europe and is expected to be approved for sale in Australia and New Zealand in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?